Literature DB >> 28167384

A live-attenuated influenza vaccine for H3N2 canine influenza virus.

Laura Rodriguez1, Aitor Nogales1, Emma C Reilly2, David J Topham2, Pablo R Murcia3, Colin R Parrish4, Luis Martinez Sobrido5.   

Abstract

Canine influenza is a contagious respiratory disease in dogs caused by two subtypes (H3N2 and H3N8) of canine influenza virus (CIV). Currently, only inactivated influenza vaccines (IIVs) are available for the prevention of CIVs. Historically, live-attenuated influenza vaccines (LAIVs) have been shown to produce better immunogenicity and protection efficacy than IIVs. Here, we have engineered a CIV H3N2 LAIV by using the internal genes of a previously described CIV H3N8 LAIV as a master donor virus (MDV) and the surface HA and NA genes of a circulating CIV H3N2 strain. Our findings show that CIV H3N2 LAIV replicates efficiently at low temperature but its replication is impaired at higher temperatures. The CIV H3N2 LAIV was attenuated in vivo but induced better protection efficacy in mice against challenge with wild-type CIV H3N2 than a commercial CIV H3N2 IIV. This is the first description of a LAIV for the prevention of CIV H3N2 in dogs.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Attenuated (att); Canine influenza virus (CIV); Cold adapted (ca); Inactivated influenza vaccine (IIV); Influenza A virus (IAV); Live-attenuated influenza vaccine (LAIV); Master donor virus (MDV); Reverse genetics techniques; Temperature sensitive (ts)

Mesh:

Substances:

Year:  2017        PMID: 28167384     DOI: 10.1016/j.virol.2017.01.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  Interplay of PA-X and NS1 Proteins in Replication and Pathogenesis of a Temperature-Sensitive 2009 Pandemic H1N1 Influenza A Virus.

Authors:  Aitor Nogales; Laura Rodriguez; Marta L DeDiego; David J Topham; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

2.  Generation and Characterization of Single-Cycle Infectious Canine Influenza A Virus (sciCIV) and Its Use as Vaccine Platform.

Authors:  Aitor Nogales; Kevin Chiem; Michael Breen; Marta L DeDiego; Colin R Parrish; Luis Martínez-Sobrido
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine.

Authors:  Luis Martínez-Sobrido; Olve Peersen; Aitor Nogales
Journal:  Viruses       Date:  2018-10-15       Impact factor: 5.048

Review 4.  Novel Approaches for The Development of Live Attenuated Influenza Vaccines.

Authors:  Pilar Blanco-Lobo; Aitor Nogales; Laura Rodríguez; Luis Martínez-Sobrido
Journal:  Viruses       Date:  2019-02-22       Impact factor: 5.048

5.  Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine.

Authors:  Thomas A Hilimire; Aitor Nogales; Kevin Chiem; Javier Ortego; Luis Martinez-Sobrido
Journal:  Pathogens       Date:  2020-01-29

Review 6.  Canine Infectious Respiratory Disease.

Authors:  Krystle L Reagan; Jane E Sykes
Journal:  Vet Clin North Am Small Anim Pract       Date:  2019-12-05       Impact factor: 2.093

7.  Spread of Canine Influenza A(H3N2) Virus, United States.

Authors:  Ian E H Voorhees; Amy L Glaser; Kathy Toohey-Kurth; Sandra Newbury; Benjamin D Dalziel; Edward J Dubovi; Keith Poulsen; Christian Leutenegger; Katriina J E Willgert; Laura Brisbane-Cohen; Jill Richardson-Lopez; Edward C Holmes; Colin R Parrish
Journal:  Emerg Infect Dis       Date:  2017-12-17       Impact factor: 6.883

8.  Development of a novel equine influenza virus live-attenuated vaccine.

Authors:  Laura Rodriguez; Stephanie Reedy; Aitor Nogales; Pablo R Murcia; Thomas M Chambers; Luis Martinez-Sobrido
Journal:  Virology       Date:  2018-01-11       Impact factor: 3.616

9.  Swine ANP32A Supports Avian Influenza Virus Polymerase.

Authors:  Thomas P Peacock; Olivia C Swann; Hamish A Salvesen; Ecco Staller; P Brian Leung; Daniel H Goldhill; Hongbo Zhou; Simon G Lillico; C Bruce A Whitelaw; Jason S Long; Wendy S Barclay
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

Review 10.  Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile.

Authors:  Thomas P Monath; Jeroen Kortekaas; Douglas M Watts; Rebecca C Christofferson; Angelle Desiree LaBeaud; Brian Gowen; Clarence J Peters; Darci R Smith; Robert Swanepoel; John C Morrill; Thomas G Ksiazek; Phillip R Pittman; Brian H Bird; George Bettinger
Journal:  Vaccine X       Date:  2020-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.